Effect of Ang-2-VEGF-A Bispecific Antibody in Renal Cell Carcinoma.

Bessho, Hideharu; Wong, Bernice; Huang, Dachuan; Tan, Jing; Ong, Choon Kiat; Iwamura, Masatsugu; Hart, Stefan; Dangl, Markus; Thomas, Markus; Teh, Bin Tean

Bessho, Hideharu; Wong, Bernice; Huang, Dachuan; Tan, Jing; Ong, Choon Kiat; Iwamura, Masatsugu; Hart, Stefan; Dangl, Markus; Thomas, Markus; Teh, Bin Tean.

Afiliação

Bessho H; a Laboratory of Cancer Epigenome , National Cancer Centre Singapore , Singapore.
Wong B; b Program in Cancer and Stem Cell Biology , Duke-NUS Graduate Medical School , Singapore.
Huang D; c Department of Urology , Kitasato University School of Medicine , Kanagawa , Japan.
Tan J; a Laboratory of Cancer Epigenome , National Cancer Centre Singapore , Singapore.
Ong CK; b Program in Cancer and Stem Cell Biology , Duke-NUS Graduate Medical School , Singapore.
Iwamura M; a Laboratory of Cancer Epigenome , National Cancer Centre Singapore , Singapore.
Hart S; b Program in Cancer and Stem Cell Biology , Duke-NUS Graduate Medical School , Singapore.
Dangl M; a Laboratory of Cancer Epigenome , National Cancer Centre Singapore , Singapore.
Thomas M; b Program in Cancer and Stem Cell Biology , Duke-NUS Graduate Medical School , Singapore.
Teh BT; a Laboratory of Cancer Epigenome , National Cancer Centre Singapore , Singapore.

Cancer Invest ; 33(8): 378-86, 2015.

Article em En | MEDLINE | ID: mdl-26115098

RESUMO

The blockade of VEGF pathway has been clinically validated as an initial treatment for renal cell carcinoma (RCC). Angiopoietin-2 (Ang-2) has been indicated as a key regulator for angiogenesis escape. The effect of a novel bispecific antibody (A2V CrossMab) against both Ang-2 and VEGF was investigated in comparison with either factor. A2V CrossMab significantly reduced tumor volume, vessel density, and interstitial fluid pressure compared to either monotherapy of anti-VEGF or anti-Ang-2. Host-derived angiogenesis-related genes have been significantly down-regulated in A2V CrossMab group. These data demonstrate that A2V CrossMab has additive anti-tumor effect for the treatment of RCC.

Assuntos

Angiopoietina-2/imunologia; Anticorpos Biespecíficos/farmacologia; Carcinoma de Células Renais/tratamento farmacológico; Neoplasias Renais/tratamento farmacológico; Fator A de Crescimento do Endotélio Vascular/imunologia; Angiopoietina-2/antagonistas & inibidores; Angiopoietina-2/metabolismo; Animais; Anticorpos Biespecíficos/imunologia; Carcinoma de Células Renais/genética; Análise por Conglomerados; Feminino; Regulação Neoplásica da Expressão Gênica/efeitos dos fármacos; Humanos; Neoplasias Renais/genética; Camundongos Nus; Neovascularização Patológica/tratamento farmacológico; Neovascularização Patológica/genética; Fator A de Crescimento do Endotélio Vascular/antagonistas & inibidores; Fator A de Crescimento do Endotélio Vascular/metabolismo; Ensaios Antitumorais Modelo de Xenoenxerto

Palavras-chave

Angiopoietin; Anti-angiogenic therapy; Interstitial fluid pressure; Renal cell carcinoma; VEGF

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Carcinoma de Células Renais / Anticorpos Biespecíficos / Angiopoietina-2 / Fator A de Crescimento do Endotélio Vascular / Neoplasias Renais Tipo de estudo: Prognostic_studies Limite: Animals / Female / Humans Idioma: En Ano de publicação: 2015 Tipo de documento: Article

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google